Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Lakewood-Amedex Biotherapeutics in a report released on Wednesday, October 28th. HC Wainwright analyst M. Keller expects that the company will earn ($1.85) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is $4.96 per share. HC Wainwright also issued estimates for Lakewood-Amedex Biotherapeutics’ Q4 2026 earnings at ($1.44) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.29) EPS and FY2029 earnings at ($1.59) EPS.
A number of other research firms have also weighed in on LABT. Weiss Ratings upgraded shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Wall Street Zen upgraded Lakewood-Amedex Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 6th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold”.
Lakewood-Amedex Biotherapeutics Price Performance
Shares of Lakewood-Amedex Biotherapeutics stock opened at $0.24 on Friday. Lakewood-Amedex Biotherapeutics has a one year low of $0.22 and a one year high of $98.20. The company has a 50-day moving average price of $1.43.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($2.75) earnings per share for the quarter.
Lakewood-Amedex Biotherapeutics Company Profile
Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.
The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.
Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.
Featured Articles
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- 5 Stocks to Buy in November: Bargains Worth Giving Thanks For
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
